30 Aug, 2026
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. A newly acquired Novartis drug successfully lowered signs…
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech…
Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer…
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and…
WASHINGTON — President Trump and health secretary Robert F. Kennedy Jr. are pressing ahead with efforts to change how kids in the U.S. get their shots.  The latest move, a…

Novartis drug cuts inflammation. A heart outcomes study is to come

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. A newly acquired Novartis drug successfully lowered signs of inflammation in a midstage study, as experts wait to hear how the company plans to advance the drug as a potential cardiovascular treatment.  In […]

2 mins read

A look at Trump loyalist Heidi Overton, newly nominated as FDA chief

Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of health care. Confidential tips can be sent on Signal at danielp.100. WASHINGTON — The Trump administration did not overhaul the childhood vaccine schedule or flip the […]

3 mins read

Sanofi to lay off 229 workers in Mass., a year after Blueprint Medicines acquisition

Sanofi, one of Massachusetts’ largest pharmaceutical employers, will lay off 229 workers, according to records the company filed with the state. The workers losing their jobs have been employed with Blueprint Medicines, a Cambridge-based biotech that Sanofi acquired in a $9.1 billion deal in July 2025. The workers’ positions will be cut between Oct. 9 […]

2 mins read